Study on the Mechanism of Neurodevelopment Dysplasia of Fetal Brain Caused by ASNS Gene Mutation
NCT ID: NCT03587155
Last Updated: 2018-07-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
10 participants
OBSERVATIONAL
2017-10-28
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diagnosis of Prader-Willi Syndrome and Angelman Syndrome
NCT04155944
Genomic Study of Congenital Malformation
NCT01250613
Investigation of Human Alpha-fetoprotein Genes
NCT01258894
Genetic Biomarkers Associated With Child Language Development in Taiwan (II)
NCT05510570
Genetic Polymorphism and Parkinson's Disease in Taiwanese
NCT01996878
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mutation
Embryo or infant with ASNS mutation.
No interventions assigned to this group
Control
Embryo or infant without ASNS mutation.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Control Group: No ASNS gene mutation by DNA exon sequencing.
Exclusion Criteria
* Control Group: Having other gene mutation which also effect neurodevelopment.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Natural Science Foundation of China
OTHER_GOV
The First Hospital of Jilin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bo Chen
Associate Chief Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bo Chen, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
The First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bo Chen
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASNS-BRAIN001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.